Cambridge Investment Research Advisors Inc. Sells 40,959 Shares of OPKO Health (NASDAQ:OPK)

Cambridge Investment Research Advisors Inc. lowered its stake in shares of OPKO Health (NASDAQ:OPK) by 8.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 448,269 shares of the biotechnology company’s stock after selling 40,959 shares during the quarter. Cambridge Investment Research Advisors Inc. owned 0.08% of OPKO Health worth $1,421,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. X Square Capital LLC bought a new position in shares of OPKO Health during the 4th quarter valued at $2,363,000. Delek Group Ltd. bought a new position in shares of OPKO Health during the 4th quarter valued at $382,000. Boulegeris Investments Inc. grew its holdings in shares of OPKO Health by 19.3% during the 4th quarter. Boulegeris Investments Inc. now owns 228,780 shares of the biotechnology company’s stock valued at $1,121,000 after purchasing an additional 36,950 shares during the last quarter. Kovack Advisors Inc. bought a new position in shares of OPKO Health during the 4th quarter valued at $671,000. Finally, Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of OPKO Health by 18.0% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 340,326 shares of the biotechnology company’s stock valued at $1,668,000 after purchasing an additional 51,890 shares during the last quarter. Hedge funds and other institutional investors own 24.21% of the company’s stock.

Several equities analysts recently commented on OPK shares. ValuEngine lowered shares of OPKO Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $20.00 target price on shares of OPKO Health and gave the company a “buy” rating in a report on Thursday, March 1st. JPMorgan Chase & Co. lowered shares of OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 price target on the stock. in a report on Friday, March 2nd. Zacks Investment Research lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. Finally, BidaskClub raised shares of OPKO Health from a “strong sell” rating to a “sell” rating in a report on Thursday, April 19th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. OPKO Health currently has a consensus rating of “Hold” and a consensus price target of $10.21.



Shares of OPKO Health opened at $4.48 on Friday, Marketbeat.com reports. The firm has a market capitalization of $2.36 billion, a price-to-earnings ratio of -15.45 and a beta of 1.67. OPKO Health has a 12-month low of $2.66 and a 12-month high of $7.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.94 and a current ratio of 1.10.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $254.90 million for the quarter, compared to analyst estimates of $236.90 million. OPKO Health had a negative net margin of 31.27% and a negative return on equity of 8.76%. The company’s revenue was down 4.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.06) EPS. research analysts expect that OPKO Health will post -0.27 earnings per share for the current fiscal year.

In related news, CEO Phillip Md Et Al Frost bought 40,000 shares of the business’s stock in a transaction dated Monday, March 19th. The shares were purchased at an average price of $3.51 per share, with a total value of $140,400.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $10,772,018.01. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Robert Scott Fishel bought 15,000 shares of the business’s stock in a transaction dated Monday, April 16th. The shares were bought at an average cost of $3.01 per share, for a total transaction of $45,150.00. The disclosure for this purchase can be found here. Insiders have bought a total of 1,189,402 shares of company stock worth $3,913,998 in the last ninety days. Insiders own 42.74% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Institutional Ownership by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply